Introduction {#Sec1}
============

Psoriasis is a common chronic immune-mediated disease \[[@CR1]\] which impairs patients' quality of life significantly \[[@CR2], [@CR3]\]. The treatment of moderate-to-severe psoriasis used to be difficult \[[@CR4]\], but improved understanding of the immunopathogenesis of psoriasis has led to the development of highly effective targeted therapies, mainly biologics, in the last decade \[[@CR5]\]. Currently, reductions in the psoriasis area and severity index (PASI) of 75% or even 90% are expected in the majority of patients since the introduction of anti-IL17 drugs \[[@CR6]\].

Biologic therapy is mainly used in patients with moderate-to-severe psoriasis and often in those who failed phototherapy and systemic therapy. Most patients meeting the criteria in clinical trials had a disease history of more than 10 years \[[@CR7], [@CR8]\], and usually experience disease relapse after treatment discontinuation. Nevertheless, hypotheses have been proposed that early treatment may result in better clinical control and even alter the natural course of the disease in the long term \[[@CR9]--[@CR11]\].

Long-term treatment is recommended for patients with psoriasis because of its chronic relapsing nature. Yet, treatment duration in clinical trials of biologics varies between 3 months and at most 5 years, and drug discontinuation is inevitable after the end of the trials. In real-world practice, treatment interruption is also common, mainly because of loss of efficacy \[[@CR12]\]. Thus, it is important to understand the remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics after treatment discontinuation.

In our study, we evaluated clinical relapse in biologics and tofacitinib responders with moderate-to-severe psoriasis who discontinued trial drugs. Clinical features predictive of long-term remission were analyzed and long-term severe adverse events were collected.

Methods {#Sec2}
=======

We retrospectively included 184 patients with moderate-to-severe psoriasis who participated in 11 biologic or tofacitinib clinical studies conducted between 2004 and 2016 in our clinic (Table [1](#Tab1){ref-type="table"}). Medications prescribed included efalizumab \[[@CR13]\], alefacept \[[@CR14]\], etanercept \[[@CR15], [@CR16]\], ustekinumab \[[@CR17]\], secukinumab \[[@CR18], [@CR19]\], tofacitinib \[[@CR20], [@CR21]\], ixekizumab \[[@CR22]\], and guselkumab \[[@CR23]\] (in time sequence). During safety follow-up periods of the trials, subjects were free from concomitant systemic therapy per protocols. All treatments were given as monotherapy, yet 37 patients took part in multiple trials; therefore, 232 courses of therapies were given. Participants were at least 20 years old with a diagnosis of plaque psoriasis which involved at least 10% body surface area (BSA) at baseline with PASI at least 10 or 12 according to protocols.Table 1Trial list and patient demographicsTrial agentEfalizumab \[[@CR13]\]Alefacept \[[@CR14]\]Etanercept \[[@CR15]\]Etanercept \[[@CR16]\]Tofacitinib \[[@CR20]\]Tofacitinib \[[@CR21]\]NCT numberNCT00602823NCT00422617NCT00245960NCT00663052NCT01276639NCT01815424Mode of actionCD11aFusion CD2/T cellFusion/receptorTNFFusion/receptorTNFJAKJAKAcronymPRESTAPRISTINEDefinition of moderate-to-severe psoriasisPASI ≥ 12 and BSA ≥ 10%PASI ≥ 12 and BSA ≥ 10%GA score ≥ 3 and BSA ≥ 10%PASI ≥ 10 and BSA ≥ 10%PASI ≥ 12, PGA score ≥ 3, and BSA ≥ 10%PASI ≥ 12, PGA score ≥ 3, and BSA ≥ 10%InterventionEfalizumab 1 mg/kg once QWAlefacept 15 mg QWEtanercept 50 mg BIW or QW for 12 weeks, then QW for 12 weeksEtanercept 50 mg BIW or QW for 12 weeks, then QW for 12 weeksTofacitinib 5 or 10 mg or placebo BIW. Placebo arm was re-randomized to receive tofacitinib 5 or 10 mg BID at week 16Tofacitinib 5 or 10 mg or placebo BIW. Placebo arm was re-randomized to receive tofacitinib 5 or 10 mg BID at week 16Duration of treatment12 weeks, with 12-week treatment-free follow-up12 weeks, with 12-week treatment-free follow-up12-week double-blind period and 12-week open-label period, with 2-week follow-up12-week double-blind period and 12-week open-label period, with 2-week follow-up52 weeks and open-label extension up to 5 years52 weeksAge, mean ± SD56.2 ± 12.250.6 ± 13.350.7 ± 15.245.9 ± 9.343.3 ± 12.240.5 ± 12.2Weight (kg), mean ± SD70.7 ± 12.774.6 ± 13.273.7 ± 19.774.6 ± 11.777.7 ± 16.670.6 ± 14.4Duration since diagnosis (years), mean ± SD2.5 ± 2.82.0 ± 2.11.6 ± 2.32.8 ± 2.15.6 ± 2.93.8 ± 2.8Biologic naive,*n* (%)25 (100.0%)8 (57.1%)11 (73.3%)14 (87.5%)14 (54.8%)12 (85.7%)Baseline PASI, mean ± SD27.2 ± 12.619.9 ± 11.423.6 ± 12.823.6 ± 8.121.1 ± 9.126.2 ± 12.9Trial agentIxekizumab \[[@CR22]\]Secukinumab \[[@CR18]\]Secukinumab and ustekinumab \[[@CR19]\]Ustekinumab \[[@CR17]\]Ustekinumab and guselkumab \[[@CR23]\]PooledNCT numberNCT02513550NCT01365455, NCT01544595NCT02074982NCT00747344NCT02203032Mode of actionIL17IL17Secukinumab: IL17; ustekinumab: IL12/IL23IL12/IL23Ustekinumab: IL12/IL23; guselkumab: IL23AcronymIXORA-PERASURECLEARPEARLNAVIGATEDefinition of moderate-to-severe psoriasisPASI ≥ 12 and PGA score ≥ 3PASI ≥ 12, PGA score ≥ 3, and BSA ≥ 10%PASI ≥ 12, PGA score ≥ 3, and BSA ≥ 10%PASI ≥ 12 and BSA ≥ 10%PASI ≥ 12, PGA score ≥ 3, and BSA ≥ 10%InterventionIxekizumab 80 mg Q2W or Q4WSecukinumab 300 mg or 150 mg QW for 4 weeks, then monthly until week 48Secukinumab 300 mg QW for 4 weeks, then Q4W until week 48. Ustekinumab 45 or 90 mg at week 0, 4, 16, 28, 40Ustekinumab 45 mg at weeks 0, 4, 16 or placebo at weeks 0, 4 and ustekinumab 45 mg at weeks 12, 16Ustekinumab 45 or 90 mg at weeks 0, 4. Guselkumab 100 mg at weeks 16, 20, 28, 36, 44 or ustekinumab 45 or 90 mg at weeks 16, 28, 40Duration of treatment52 weeks12-week induction period and 40-week maintenance period, with 8-week follow-up2 years for secukinumab arm and 1 year for ustekinumab arm12-week placebo-controlled period, with follow-up until week 3616-week open-label period and 28-week randomized period, with 16-week follow-upAge, mean ± SD47.4 ± 10.427.4 ± 12.148.7 ± 17.153.0 ± 12.443.4 ± 12.248.6 ± 13.3Weight (kg), mean ± SD93.9 ± 20.880.2 ± 17.072.5 ± 16.577.3 ± 14.775.6 ± 12.476.6 ± 16.6Duration since diagnosis (years), mean ± SD4.7 ± 4.06.9 ± 3.85.0 ± 2.42.8 ± 2.64.9 ± 3.24.1 ± 3.3Biologic naive,*n* (%)10 (66.7%)21 (61.8%)14 (58.3%)22 (73.3%)6 (42.9%)160 (69.0%)Baseline PASI, mean ± SD24.8 ± 11.423.1 ± 8.520.9 ± 8.323.9 ± 10.223.3 ± 11.123.3 ± 10.3Clinical demographics of the trials that are included in this study and pooled data are arranged by mode of action. Key inclusion criteria, intervention agent, and duration of each trial were provided*NCT number* clinicaltrials.gov identifier, *PASI* psoriasis area and severity index, *TNF* tumor necrosis factor, *JAK* Janus kinase

Subjects from 11 studies were evaluated separately and also pooled to evaluate time to relapse and outcome. Clinical relapse of psoriasis was defined as the 5-item scale Physician's Global Assessment (PGA) ≥ 2, or initiation of oral systemic anti-psoriasis agents (methotrexate, acitretin, and cyclosporine), phototherapy, or biological therapy after achieving at least 75% reduction in PASI (PASI 75) compared to baseline. In our clinical practice, patients with unstable courses, occurrence of many newly onset lesions, extensive plaques, significantly impaired quality of life, or pruritic plaques resistant to topical treatment were given systemic treatment. Relapse-free duration was defined as the period between relapse and the last administration of investigational agent. Biologics were given when patients met the inclusion criteria of further trials or the reimbursement guideline set by the national health insurance. The latter was PASI and BSA at least 10 in patients who had failed, were intolerant, or contraindicated to two out of three conventional systemic agents (methotrexate, acitretin, and cyclosporine) and phototherapy, each for 12 weeks. Long-term outcome was evaluated on the basis of medical records and patient interviews, and was collected during the trial follow-up periods and also after the trials. Special attention was paid for new-onset inflammatory joint pain suggestive of psoriatic arthritis and erythroderma (BSA ≥ 75%) which developed after discontinuation of investigational agents. Patients who missed office appointments were contacted by telephone. In accordance with the 1996 Declaration of Helsinki and Good Clinical Practice guidelines, ethical approvals were obtained from the National Taiwan University Research Ethics Committee for all trials.

Statistical Analysis {#Sec3}
--------------------

To compare intergroup discrepancy, Student's *t* test and the Wilcoxon test were used for continuous variables and the Fisher's exact or Chi-square tests were applied for discrete variables. Generalized estimating equation (GEE) was implemented to estimate predictors of duration to relapse after withdrawal of biologics. GEE methodology has taken into consideration for multiple treatment courses of the same patient. Confounding factors including age, sex, body weight, and psoriatic arthritis (PsA) were taken into account in the GEE analysis. Survival analysis was executed to evaluate the proportions of relapse-free subjects. Kaplan--Meier analysis with log rank test (Mantel--Cox test) was performed to assess the difference between early and delayed biologic intervention, patients who achieved PASI 90 and those who only achieved PASI 75, and biologic-naive and biologic-experienced patients. Two-tailed tests were conducted and a*p* value less than 0.05 was considered statistically significant. Analyses were carried out using SPSS version 25.

Results {#Sec4}
=======

Patient demographics and clinical outcomes are shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Mean follow-up duration was 83 months, while the median duration was 4.7 years (range 0.1--14.4). Among patients without a previous history of arthritis, 40 patients developed arthralgia/arthritis after discontinuation of biologics in a total of 1432.2 person-years (PY) of follow-up. Pooled data showed an incidence rate of 2.8/100 PY. PsA was most commonly observed in patients who discontinued efalizumab (*n* = 12), but intergroup differences were not significant. On the contrary, newly developed arthritis was not documented in the NAVIGATE protocol. The incidence rate of erythrodermic psoriasis varied, with the highest one observed in the ERASURE study (7.4/100 PY). No patients experienced erythroderma after the PRESTA study. Generalized pustular psoriasis was observed in one subject who was injected with secukinumab during the entire follow-up period of this pooled analysis.Table 2Long-term outcome and SAETrial agentEfalizumab \[[@CR13]\]Alefacept \[[@CR14]\]Etanercept \[[@CR15]\]Etanercept \[[@CR16]\]Tofacitinib \[[@CR20]\]Tofacitinib \[[@CR21]\]NCT numberNCT00602823NCT00422617NCT00245960NCT00663052NCT01276639NCT01815424Number of treatment courses251415163114Follow-up duration (years), median (min--max)14.1 (2.5--14.4)13.6 (0.3--13.8)10.9 (1.2--12.3)8.9 (0.1--9.4)4.1 (0.2--7.4)3.6 (2.9--4.5)Cumulative relapse-free rate at 6 months,  %0066.7%66.7%33.3%0Cumulative relapse-free rate at 12 months,  %0050%33.3%12.5%0New arthritis,*n* (events/100 PY)12 (3.7)2 (1.3)0^a^ (0)3 (2.6)4 (3.0)5 (10.1)Erythrodermic psoriasis,*n* (events/100 PY)7 (2.2)2 (1.3)0 (0)3 (2.6)4 (3.0)1 (2.0)Pustular psoriasis,*n* (events/100 PY)0 (0)0 (0)0 (0)0 (0)0 (0)0 (0)SAE,*n* (events/100 PY)4 (1.6)2 (1.2)4 (2.9)2 (1.8)1 (0.8)0 (0)MACE,*n* (events/100 PY)1 (0.3)1 (0.6)2 (2.1)1 (0.9)1 (0.7)0 (0)Trial agentIxekizumab \[[@CR22]\]Secukinumab \[[@CR18]\]Secukinumab and ustekinumab \[[@CR19]\]Ustekinumab \[[@CR17]\]Ustekinumab and guselkumab \[[@CR23]\]PooledNCT numberNCT02513550NCT01365455, NCT01544595NCT02074982NCT00747344NCT02203032Number of treatment courses1534243014232Follow-up duration (years), median (min--max)2.3 (0.5--2.4)2.6 (0.1--7.1)3.2 (2.1--4.3)9.5 (0.9--9.7)3.1 (2.0--3.3)4.7 (0.1--14.4)Cumulative relapse-free rate at 6 months,  %29.2%16.7%22.2%73.3%031.3%Cumulative relapse-free rate at 12 months,  %9.7%11.1%027.5%013.9%New arthritis,*n* (events/100 PY)4 (12.2)5 (5.3)4 (5.3)1 (0.4)0 (0)40 (2.8)Erythrodermic psoriasis,*n* (events/100 PY)1 (3.9)7 (7.4)4 (5.3)2 (0.7)1 (2.4)32 (2.2)Pustular psoriasis,*n* (events/100 PY)0 (0)0 (0)1 (1.3)0 (0)0 (0)1 (0.1)SAE,*n* (events/100 PY)0 (0)2 (2.1)2 (2.6)3 (1.1)0 (0)21 (1.5)MACE,*n* (events/100 PY)0 (0)0 (0)2 (2.6)3 (1.1)0 (0)12 (0.8)PRESTA inclusion criteria required subjects to be diagnosed with psoriatic arthritis. Long-term outcome and SAE of the trials numbered in Table [1](#Tab1){ref-type="table"} were collected during and after the administration of biologics. Cumulative relapse-free rates were derived from Kaplan--Meier survival analysis*NCT number* clinicaltrials.gov identifier, *SAE* serious adverse events, *MACE* major adverse cardiovascular events

Serious adverse events (SAE), as defined by the International Conference on Harmonization, developed in 21 subjects during a median follow-up of 60.5 months. The incidence rate of SAE was 1.5 per 100 PY. The most common SAE was cerebral vascular event (*n* = 7), followed by death (*n* = 5). Causes of death included two cardiac arrests, two heart failures, and one pancreatic cancer. Malignancy accounted for four cases, specifically two nasopharyngeal cancers, one colon cancer, and one parotid cancer. Other issues were acute retinal necrosis (*n* = 2), chronic kidney disease (*n* = 2), and coronary artery disease. Among different studies, SAE were observed in most trials except the tofacitinib in Asian, the IXORA-P, and the NAVIGATE study.

Of the 232 treatment courses screened for eligibility, a total of 95 treatment courses achieved PASI 75 at the end of each study. Median time to relapse was 7.6 months. Regarding the relapse-free rate for each study, all of the PASI 75 responders who received efalizumab (4/25), alefacept (1/14), the Asian tofacitinib trial (NCT01815424) (5/14), and guselkumab (*n* = 10/14) relapsed within 5 months. At 6 months after treatment discontinuation, the relapse-free rates of our patients who entered the PRESTA, PRISTINE, PEARL, ERASURE, CLEAR, the global tofacitinib study (NCT01815424), and the IXORA-P study were 66.7%, 66.7%, 75.0%, 16.7%, 22.2%, 33.3%, and 29.2%, respectively. At 12 months, the proportions were 50%, 33.3%, 33.3%, 11.1%, 0, 16.7%, and 16.7%, respectively. In total, the proportions of relapse-free treatment episodes were 16.8% (16/95) at 1 year, 7.4% (7/94) at 2 years, 4.3% (4/93) at 3 years, 3.2% (3/93) at 4 years, and 3.2% (3/93) at 5 years. Biologics were reinitiated in 41.9% (39/93) at 1 year, 66.7% (62/93) at 2 years, 77.1% (64/83) at 3 years, 83.5% (66/79) at 4 years, and 86.1% (68/79) at 5 years after the end of the trials.

Predictors for remission duration were estimated with 95 treatment courses in patients who had achieved PASI 75 at the end of the trials (Table [3](#Tab3){ref-type="table"}). After correction of the covariates including age, sex, body weight and PsA at baseline, multivariate GEE regression analysis demonstrated that predictors for a longer relapse-free duration after biologic cessation were baseline PASI \[95% confidence interval (CI) − 0.226, − 0.074; *p* \< 0.001), PASI improvement during treatment (95% CI 0.062, 0.204; *p* \< 0.001), biologic naivety (95% CI 0.213, 1.007; *p* \< 0.001), and early biologic intervention (95% CI 0.457, 1.046; *p* = 0.003).Table 3Predictors of psoriasis relapse after withdrawal of biologicsEstimated coefficientsStandard error95% CI*p* valueBody weight− 0.0010.0041− 0.009, 0.0070.783Baseline PASI− 0.1500.0388− 0.226, − 0.074\<  0.001Baseline PsA Yes0.0740.1597− 0.239, 0.3870.642 NoReference groupPASI improvement during treatment0.1330.03640.062, 0.204\< 0.001Biologic naive Yes0.6100.20260.213, 1.007\< 0.001 NoReference groupEarly biologic intervention Yes0.7510.15030.457, 1.0460.003 NoReference groupPredicting factors demonstrated by GEE multivariant analysis were baseline PASI (*p* \< 0.001), PASI improvement during treatment (*p* \< 0.001), biologic naivety (*p* \< 0.001), and early biologic intervention (*p* = 0.003) after correcting the covariates including age, sex, body weight and PsA at baseline*PASI* psoriasis area and severity index, *PsA* psoriatic arthritis

A total of 95 (40.9%) treatment episodes reached PASI 75 at the end of the trials. Patients were further grouped by the duration between the diagnosis of psoriasis and the initiation of the trial drugs, PASI improvement at the end of the studies, and status of previous biological treatment experience (Table [4](#Tab4){ref-type="table"}). Patients who received early biologic intervention within 2 years of diagnosis showed significantly higher relapse-free rates by Kaplan--Meier analysis with log rank test (*p* = 0.002) (Fig. [1](#Fig1){ref-type="fig"}). The median time to relapse for early and delayed biologic intervention was 15 and 27 weeks. At 6, 12, and 24 months, the cumulative relapse-free rates for early versus delayed administration of biologic group were 51.5% versus 22.6%, 33.3% versus 8.1% and 15.2% versus 4.8%, respectively.Table 4Relapse-free duration after biologics cessation (months)MeanStandard error95% CIPooled7.6351.5014.693, 10.578Biologic intervention (*p* = 0.002) Early (*n* = 33)23.8648.1677.855, 39.872 Delayed (*n* = 62)5.3550.8243.740, 6.970Biologic naivety (*p* \< 0.001) Naive (*n* = 69)17.6345.0337.769, 27.499 Experienced (*n* = 26)3.2600.6142.055, 4.464PASI improvement (*p* = 0.006) PASI 90 (*n* = 47)15.5054.6196.452, 24.558 PASI 75 (*n* = 48)11.1724.8231.719, 20.625Speed to achieve PASI 75 (*p* = 0.250) ≤ 12 weeks (*n* = 64)17.9005.4107.297, 28.503 \> 12 weeks (*n* = 31)6.2581.4313.453, 9.064PASI 75 patients were grouped according to timing of biologic intervention, biologic naivety, and PASI improvement during trial. Early biologic intervention (*p* = 0.002), biologic naivety (*p* \< 0.001), and PASI 90 (*p* = 0.006) were associated with higher relapse-free rates with Kaplan--Meier survival analysis. *p* values were calculated using Log rank test*PASI* psoriasis area and severity indexFig. 1Relapse-free rates after discontinuing biologics. Survival functions derive from Kaplan--Meier curves demonstrated the difference in relapse interval after biologics cessation. Stratified survival curves demonstrated significant longer relapse-free duration of biologic naivety (*p* \< 0.001), early-biologic intervention (*p* = 0.002) and patients reaching PASI 90 at end of trials (*p* = 0.006). *PASI* psoriasis area and severity index

The treatment courses in patients who were biologic naive demonstrated a smaller proportion of relapse by survival analysis when compared with those who experienced biologics (*p* \< 0.001). Lower relapse rate was also observed in patients who achieved PASI 90 when compared to those achieved PASI 75 (*p* = 0.006) (Fig. [1](#Fig1){ref-type="fig"}). The patients who reached a PASI 90 at the end of the trial had a similar median time to relapse of 5.5 months as those who were biologic naive irrespective of PASI at the end of the trial. Subjects who reached PASI 90 showed a higher relapse-free rate compared to those who only achieved PASI 75 at 6 months (46.8% cf. 18.7%) and 1 year (21.3% and 12.5%). Those who were never exposed to biologics also demonstrated better relapse-free rate compared to those who failed previous biologics at 6 months (25% cf. 23.3%) and 1 year (11.4% and 5.7%).

Discussion {#Sec5}
==========

The goal of anti-psoriatic treatments has been revised in the light of modern targeted immune therapies which showed dramatic efficacy \[[@CR5]\]. The efficacy expectation has evolved beyond greater PASI reduction to include faster onset, better drug sustainability, longer remission duration, and recapture of efficacy after reinitiation. Despite the advance in treatment, some questions remain underexplored, such as the possibility of disease modification or predictors for long-term remission. Long-term outcomes after treatment discontinuation were also poorly studied. In controlled studies, patients were typically followed up for 2 weeks \[[@CR21], [@CR24]\] to 12 weeks \[[@CR23]\] after the end of study for safety reasons. Therefore, there is a lack of knowledge about remission duration and long-term outcomes in patients with moderate-to-severe psoriasis who discontinued biologic treatments.

Before the era of biological agents, delayed systemic treatment was common. Fifty percent of patients reported experiencing at least 3 years of uncontrolled psoriasis before systemic therapy was initiated \[[@CR25]\]. A similar trend for delayed therapy was observed in biologics. The disease duration of psoriasis ranges between 12 and 20 years for patients participating in biologic trials \[[@CR26]\]. Nonetheless, the benefits of early aggressive strategy have been established in some inflammatory rheumatic diseases, including rheumatoid arthritis \[[@CR27]\], Crohn's disease \[[@CR28]\], and ankylosing spondylosis \[[@CR29]\]. A similar treatment algorithm of early aggressive intervention for psoriasis is still in its infancy, mainly because of the lack of apparent irreversible structural damage in psoriasis skin lesions \[[@CR10]\]. The current treatment guidelines in psoriasis still recommend the use of biologics only in patients with moderate-to-severe psoriasis, but do take into consideration the quality of life issue in addition to the skin severity, i.e., PASI, BSA, and PGA \[[@CR7], [@CR30]\]. In this study, unlike the definition of loss of PASI 50 proposed by the National Psoriasis Foundation Medical Advisory Board \[[@CR31]\], relapse was defined as loss of PGA 0 or 1 or need of re-treatment with systemic therapy or phototherapy. Most of our patients initiated a systemic therapy before the loss of 50% of PASI improvement. A PGA ≥ 2 is more consistent with the decision to re-treat. PASI score is a non-linear scale that does not allow reliable measurement \[[@CR28]\] of small affected or residual areas \[[@CR32], [@CR33]\], while PGA is more often used in long-term study in real-world practice \[[@CR34], [@CR35]\].

It appears that relapse occurs predominantly within the first 6 months regardless of different biologics. All patients in the efalizumab, alefacept, NAVIGATE study, and one JAK inhibitor study relapsed in the first 6 months. Higher 6 month relapse-free rates were observed in patients who used etanercept and those in the PEARL study, while they were lower for IL-17 and JAK inhibitor. Previous studies concluded that time to relapse was longest in responders who were withdrawn from alefacept, followed by ustekinumab, infliximab, adalimumab, etanercept, and efalizumab despite different definitions of relapse, treatment durations, and numbers of subjects \[[@CR36]\]. Specifically, median time to relapse for each biologic agent was 29.9 weeks (alefacept), 22 weeks (ustekinumab), 19.5 weeks (infliximab), 18 weeks (adalimumab), 12.1 weeks (etanercept), and 9.6 weeks (efalizumab), respectively, in this previous review \[[@CR36]\]. Median time to relapse was between 24 and 28 weeks in different trials of secukinumab \[[@CR37], [@CR38]\]. The proportion of patients without relapse was 21% at 1 year and 10% at 2 years after discontinuation of 300 mg secukinumab \[[@CR39]\]. As for tofacitinib, the median time to relapse was 16 weeks \[[@CR24]\]. The median time to relapse (PASI ≤ 50) for ixekizumab was 20.4 weeks in Japanese patients who achieved PASI 75 after 1 year of treatment \[[@CR40]\]. Another pooled analysis of ixekizumab revealed similar median relapse duration of approximately 20 weeks despite different relapse criteria set as static Physician's Global Assessment (sPG) ≥ 3 \[[@CR41]\]. At 6 and 12 months after ixekizumab discontinuation, 26% and 7% of patients retained their initial PASI 75 responses.

Factors such as treatment response, biologics naivety, family history of psoriasis, and use of immunosuppressant were reported to be significant predictors of relapse-free duration after withdrawal of ustekinumab \[[@CR42]\]. In the current integrated analysis of data from various biologics, predictors of more effective disease control were identified as lower baseline PASI, PASI 90, biologics naivety, and early biologic use. Lower disease severity and significant improvement are related to longer remission. Findings in our study are consistent with previously reported results \[[@CR42]\] and suggest an increasing role of biologics in the early stage of disease management. Hypotheses and ongoing studies are investigating the molecular and pathological modification caused by biological agents in psoriasis, especially when administered early and aggressively \[[@CR9], [@CR10]\]. In the survival analysis, better treatment response defined with PASI and biologics-naive treatment courses demonstrated lower relapse rates and longer drug-free periods. An early biologic intervention, i.e., within 2 years of diagnosis, is also associated with better treatment outcome in terms of relapse-free duration after cessation of systemic treatment. Although rapid response to ustekinumab was reported to be predictor of longer remission duration in a previous study \[[@CR42]\], the difference between patients achieving PASI 75 within or later than 12 weeks was not significant (*p* = 0.250) when analyzed in our combined data set. Drug onset speed and duration of effect are dependent on mode of action \[[@CR36], [@CR43]\] and thus could account for this result.

In a prior study in Chinese psoriasis patients, six patterns of the natural course of psoriasis were described \[[@CR44]\]. During the follow-up of three decades, 21.4% of patients suffered from only one episode of psoriasis, usually guttate type, which resolved within 1 year, and another 12.4% of patients experienced remission after 2 years of frequent attacks. Thus, it remains to be determined whether the longer remission observed in patients with shorter disease duration is due to disease modification from biologics or simply selecting out subjects who have a tendency for long-term remission by natural course irrespective of treatment. A controlled study has been initiated to answer this question by comparing remission duration between phototherapy and secukinumab treatment in new-onset psoriasis \[[@CR10]\].

Biologics have demonstrated an overall favorable safety profile in psoriasis patients compared to conventional systemic therapy \[[@CR45]\]. The rates of serious cardiovascular events, myocardial infarction, and cerebrovascular accidents were 20, 7, and 3 events in a 4-year etanercept study of 506 patients, indicating an incidence rate of 1.5, 0.5, and 0.2 per 100 PY, respectively \[[@CR46]\]. Our integrated data revealed a consistent safety profile. The cumulative rate of SAE was 1.5/100 PY. Major adverse cardiovascular events (MACE), defined as myocardial infarction, stroke, or cardiovascular death, happened in 12 participants in our study, giving an incidence rate of 0.8 per 100 PY, which is lower but not significant (*p* = 0.129) compared to the result from the 4-year etanercept experience \[[@CR46]\]. Similar to our result, the event rate of MACE after secukinumab, despite dosage difference, was 0.7/100 PY. The incidence rate of cerebrovascular accidents in the pooled analysis of 11 studies was comparable at 0.5 events/100 PY (*p* = 0.426). Besides, the annual event rate per 100 patients for malignancies other than skin cancers was reported to be 0.61--0.63 in patients with moderate-to-severe psoriasis who discontinued ustekinumab \[[@CR47]\]. Five participants developed malignancy during our follow-up. The incidence rate was 0.3/100 PY but not significantly lower (*p* = 0.329). No SAE was monitored in one of the tofacitinib trials, IXORA-P, and NAVIGATE study, which is significantly lower (*p* = 0.046) when compared with other trials in our study.

Estimation of the prevalence rate of PsA in the general population is still in dispute, while in patients with moderate-to-severe psoriasis it is generally believed to be approximately 2--30% \[[@CR48]\]. The incidence rate of PsA was 2.7 cases per 100 PY \[[@CR48]\], and different epidemiologic surveys came to the same conclusion that the incidence rate has increased over the past decade \[[@CR49], [@CR50]\]. High prevalence of severe psoriasis was associated with patients with psoriatic arthritis \[[@CR51]\], and paradoxical onset of arthritis was described after initiation of biologics such as etanercept and ustekinumab \[[@CR52]\]. In our report, the incidence rate of PsA after withdrawal of biologics was 2.8/100 PY, which is compatible with the background 2.7/100 PY (*p* = 0.972). The incidence rate was not significantly different between each study when analyzed by Poison regression. Of note, the incidence rate reported here is in addition to the new onset or aggravation of existing arthritis occurring during clinical trials, which was efalizumab (28.6%) \[[@CR13]\], alefacept (7%) \[[@CR14]\], etanercept (5.84%) \[[@CR16]\], ustekinumab (5%) \[[@CR17]\], secukinumab (4.01%), \[[@CR53]\]. secukinumab (10.75%), \[[@CR19]\]. tofacitinib (7.58%) \[[@CR20]\], ixekizumab (4.11%) \[[@CR22]\], guselkumab (11.9%) \[[@CR23]\].

Evident strengths of this 15-year experience are the real-world practice setting and the length of follow-up. Although the participants were trial subjects, the reinitiation of treatments was based on the need for systemic treatment, reflecting both the extent and stability of lesions as well as quality of life. This represented the actual clinical scenario in daily practice, and is consistent with the indication of current biologics i.e., moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy. This preliminary study has several potential limitations that should be considered. First, drugs with different modes of action and exposure duration were pooled together. It is theoretically not acceptable to combine the different biologic groups and analyze them even though it has been done and published by others. However, despite the different transcriptomic biomarker changes at early time points for drugs with different modes of action \[[@CR54], [@CR55]\], the residual disease genomic profile may be similar for successful treatment \[[@CR56]--[@CR58]\]. Individual drug or grouped drug action analysis would add to the article despite the small numbers. The second limitation is the retrospective study design. Nonetheless, most patients were followed by the same physician in the same clinic after the end of the studies as extensions of the prior controlled studies in a similar way until there is a need for systemic treatment. Third, there is a lack of control group and head-to-head study group to compare the adverse events as a result of a paucity of data. However, the pooled incidence risk seems comparable to the published data.

Conclusions {#Sec6}
===========

Despite the variety and efficacy of current biologics, systemic treatment was needed in 50--90.3% of patients within 12 months after treatment discontinuation, and biologics were reinitiated in 77.1% of patients after 3 years. However, early administration, namely within 2 years of diagnosis, of biological agents demonstrated a lower risk of relapse after discontinuation in patients with moderate-to-severe psoriasis. The occurrence of SAE including PsA or MACE in the long-term follow-up was comparable to the published background incidence. However, it remains to be verified if early aggressive treatment actually alters the disease course of psoriasis, and whether medications with different modes of action share the same disease-modifying potentials.
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